Taguchi T, Kimoto Y
Gan To Kagaku Ryoho. 1987 May;14(5 Pt 1):1203-7.
Effectiveness of IL-2 and LAK cells induced by IL-2 on malignant diseases was discussed. IL-2 alone administered systemically showed a poor effect, and combination of IL-2 are necessary for LAK cells to kill the target malignant cells. Adoptive immunotherapy using IL-2 and LAK cells should be applied for pulmonary and hepatic metastases. Postoperative adjuvant therapy and combination with chemotherapy will become important in the future.
讨论了白细胞介素-2(IL-2)及由IL-2诱导的淋巴因子激活的杀伤细胞(LAK细胞)对恶性疾病的疗效。单独全身给予IL-2显示效果不佳,LAK细胞杀伤靶恶性细胞需要IL-2联合使用。使用IL-2和LAK细胞的过继性免疫疗法应应用于肺和肝转移。术后辅助治疗以及与化疗联合在未来将变得重要。